Ticker Symbol: TOS/TSX
Shares Outstanding: 46 244 102
QUEBEC CITY, Sept. 28 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS)
announces another sale of its 125L Ozone Sterilizer to an American healthcare
"This customer was impressed with the financial benefits of our product
as well as with its safety aspects and its ability to help them achieve a more
environmentally responsible position in the community, which were key in the
decision making process," said Ann Hewitt, VP Sales & Marketing for TSO3 Inc.
This healthcare system has become one of the largest healthcare systems
in its region with 7,000 employees, including over 500 physicians and about 90
medical specialties and subspecialties. A national leader in medical research,
it is also one of the largest non-university based physician training centers
in the United States.
"This sale is the second one to occur in this medium-sized city,
demonstrating the influence that early adopters have on purchasing decisions
of other hospitals. We are very pleased to see our strategy of working with
influential hospitals begin to drive sales to additional accounts," added
Jocelyn Vézina, CEO for TSO3 Inc.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology whit high commercial potential. The Company's first product, the
125L Ozone Sterilizer, is designed for sterile processing centers in the
In contrast to other methods used, the ozone sterilization process
developed and patented by TSO3 meets all standards required by the evolution
in sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
The 125L Ozone Sterilizer is cleared for commercialization by the US Food
and Drug Administration and by Health Canada. TSO3 is in commercialization
phase for this first product since 2006.
TSO3 currently has more than 65 employees, about half of whom work in the
sales and marketing team.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Caroline Côté, Director, Corporate
Communications & IR, (418) 651-0003, Ext. 237, firstname.lastname@example.org; Source: TSO3